Satya is a pre-clinical stage targeted oncology company, building a portfolio of first-in-class and best-in-class therapeutics in the DDR space, in addition to other pathways/targets with potential pan-cancer applications.

We have pioneered targeting of RAD51:BRCA2 interactions as a tumor agnostic mechanism for treatment of RAD51-high cancers.

Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.